Skip to main content

Advertisement

Table 2 Particular characteristics of HIV-HCV coinfected patients according to RBV AUC 0-4h threshold (n = 23)

From: Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients

  All (n = 23) RBV AUC 0-4h<1755 μg.h/L (n = 14) RBV AUC 0-4h>1755 μg.h/L (n = 9) p value
HIV RNA <50 copies/mL, n (%) 20 (87) 11 (79) 9 (100) 0.253
HIV RNA copies/mL 50 (20–9850) 50 (20–9850) 50 (40–50) 0.687
CD4 (cells/mm3) 543 (325–1067) 498 (325–993) 543 (368–1067) 0.614
CD4% 30 (10–48) 29.5 (10–48) 32 (27–45) 0.174
Duration of HIV treatment (years) 11 (1–19) 11 (1–16) 10 (2–19) 0.825
Antiretroviral therapy, n (%)     
Protease inhibitor 14 (61) 7 (50) 7 (78)  
Nucleoside reverse transcriptase inhibitor (NRTI) 21 (91) 13 (93) 8 (89)  
Non-nucleoside reverse transcriptase inhibitor (NNRTI) 8 (35) 6 (43) 2 (22)  
Integrase inhibitor 4 (17) 1 (<1) 3 (33)  
Receptor CCR5 inhibitor 1 (<1) 0 1 (11)  
  1. Quantitative variables are expressed as median and range.